OCTOBER ICON **NEWSLETTER**

IN THIS ISSUE

As our summer comes to a close, we wanted to bring you up to date on current and upcoming news at ICON!

ELIOS SYSTEM LASER

ELTGTS, or Excimer Laser Trabeculostomy Glaucoma Treatment Study, is used in conjunction with cataract surgery to reduce intraocular pressure in patients with mild to moderate open angle glaucoma. It is a microinvasive, implant-free procedure that uses excimer laser light energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of eye fluid, or aqueous.

ICON is one of only nine sites in the United States to participate in this study.

REFER A PATIENT!

Have a patient with both cataracts and mild to moderate open angle glaucoma? Refer them over! Patients must be at least 45 years of age, be diagnosed with glaucoma, and have a cataract. ICON will do a normal cataract evaluation, and if a patient is interested in being part of the study, the surgeon will go through exclusions/inclusions to see if the patient qualifies.

Questions?

Contact our research coordinator, Chris Bosch, at: (970)205-9555

IPL THERAPY

IPL, or Intense Pulsed Light Therapy, is used to treat Meibomian Gland Dysfunction (MGD). It is a device that emits strong, short bursts of light to the skin around the eyes, which then helps reduce inflammation and allows the meibomian glands to function better.

IPL is typically done in four sessions, which are spaced two to four weeks apart.

IPL can also be used to treat many different skin conditions, such as rosacea and sunspots.

Our office is now offering IPL as a dry eye treatment!

Send a referral today.



Dr. Fox and team completing first MicroOptx Beacon implant in the US!

Dr. Fox and our research coordinators celebrating after completing the very last Phase 3 iDose surgery in the nation!

CURRENT RESEARCH

iDose by Glaukos: Great news! A total of 1150 subjects have been randomized in the Phase 3 study. It is hopeful that we will have FDA approval in 2023. Enrollment is now closed- a big thanks to everyone that sent patients our way for this study.

MicroOptx Beacon: We have enrolled 4 subjects in the Phase 1 study for the treatment of refractory glaucoma. We are currently on hold, waiting for the FDA to approve the next phase.

NOV03 (100% perfluorohexyloctane): A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled trial to evaluate the effect of NOV03 (perfluorohexyloctane) on signs and symptoms of dry eye disease associated with Meibomian Gland Dysfunction (Mojave Study). Enrollment is now closed.

CPN-301 Clobetasol Propionate: A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group study to evaluate the efficacy and safety of APP13007 for the treatment of inflammation and pain after cataract surgery. We are currently enrolling subjects for this trial.

AcrySof Vivity Toric IOL: Patient satisfaction and visual outcomes after bilateral implantation of a novel non-diffractive extended vision toric IOL. This is an after-market study to collect data on the Vivity toric IOL's that we are currently offering to patients. We are enrolling subjects for this study.

Durysta: This is an observational study after FDA approval. We are currently enrolling for this study.